Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose
- PMID: 458581
- DOI: 10.1002/jps.2600680627
Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose
Abstract
The pharmacokinetics of morphine and its derived metabolite, morphine 3-monoglucuronide, were studied in normal and bile-cannulated dogs. High doses (7.2-7.7 mg/kg iv) caused renal and biliary shutdowns and time lags in urinary drug and metabolite excretion and in biliary secretion of the hepatically formed conjugate. Intermediate doses (0.41-0.47 mg/kg iv) inhibited urine flow but not renal clearance. Low doses (0.019-0.07 mg/kg iv) had no apparent effect. Dose-related effects on the total, metabolic, and biliary clearances imply saturable enzymes and/or dose-inhibited hepatic flows, accounting for the major elimination half-lives of 83 +/- 8 and 37 +/- 13 min at the high and low doses, respectively. The slow terminal phase in plasma morphine and metabolite elimination and urinary accumulation is due apparently to the enterohepatic metabolite recirculation after biliary excretion, gastrointestinal hydrolysis, and hepatic first-pass reconjugation. Bile-cannulated dogs showed no fecal drug and no slow terminal plasma and urine elimination phases. Intravenous morphine 3-monoglucuronide was eliminated only renally and showed neither biliary excretion nor prolonged hepatically formed glucuronide elimination. Hepatic morphine clearances at normal therapeutic doses parallel hepatic blood flow and explain the lack of oral morphine bioavailability by anticipating complete first-pass liver metabolism. Renal morphine and morphine conjugate clearances were 85 (+/- 9 SEM) and 41 (+/- 4 SEM) ml/min, respectively, indicating glomerular filtration for the latter and glomerular filtration plus tubular secretion for the former. Urinary morphine and morphine conjugate excretion accounted for approximately to 83% of the dose. Biliary secretion accounted for 11-14% of the dose. Morphine showed dose-independent plasma protein binding of 36 (+/- 1 SEM) % and a red cell-plasma water partition coefficient of 1.11 +/- 0.04 SD. New equations were developed to model the discontinuous morphine and morphine metabolite pharmacokinetics.
Similar articles
-
Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine.J Pharm Sci. 1986 Dec;75(12):1127-36. doi: 10.1002/jps.2600751203. J Pharm Sci. 1986. PMID: 3559921
-
Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose.J Pharm Sci. 1985 Jan;74(1):50-6. doi: 10.1002/jps.2600740114. J Pharm Sci. 1985. PMID: 3981418
-
Pharmacokinetics of morphine and its surrogates. VII: High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs.J Pharm Sci. 1985 Nov;74(11):1203-14. doi: 10.1002/jps.2600741114. J Pharm Sci. 1985. PMID: 4087182
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
-
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. Clin Pharmacokinet. 2007. PMID: 17201457 Review.
Cited by
-
Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.Br J Clin Pharmacol. 2002 Dec;54(6):592-603. doi: 10.1046/j.1365-2125.2002.t01-1-01689.x. Br J Clin Pharmacol. 2002. PMID: 12492606
-
Evaluation of first pass effect and biliary excretion of diperdipine in the dog.Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):185-90. doi: 10.1007/BF03190202. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2253647
-
Controlled release morphine sulphate tablets--a study in normal volunteers.Br J Clin Pharmacol. 1980 May;9(5):531-4. doi: 10.1111/j.1365-2125.1980.tb05858.x. Br J Clin Pharmacol. 1980. PMID: 6994793 Free PMC article. Clinical Trial. No abstract available.
-
Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15. J Pharmacol Exp Ther. 2015. PMID: 25512370 Free PMC article.
-
The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.Br J Clin Pharmacol. 1992 Jul;34(1):53-9. doi: 10.1111/j.1365-2125.1992.tb04107.x. Br J Clin Pharmacol. 1992. PMID: 1633068 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources